Figure 5.

Effect of BCL2/FOS signature on relapse-free survival. Shown is the effect of the BCL2/FOS signature on relapse-free survival (Kaplan-Meier curves, log-rank test analysis) among the Centre Léon Bérard cohort. Group A (n = 14) contains the breast cancer samples expressing low mRNA levels of both BCL2 and FOS. Group B (n = 19) is composed of the breast cancer samples with high expression levels of at least one of these two genes.